Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib and Gemcitabine in Advanced Solid Tumors
NCT03237390Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribociclib in solid tumor (advanced stage), sponsored by Mayo Clinic. Primary endpoint: Maximum Tolerated Dose up to 21 days. Started Jan 2018; status: completed.
02
Drugs
ribociclib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03237390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237390.